Mechanisms of osteoinduction by LIM mineralization protein-1 (LMP-1)
    1.
    发明申请
    Mechanisms of osteoinduction by LIM mineralization protein-1 (LMP-1) 有权
    LIM矿化蛋白-1(LMP-1)诱导骨诱导机制

    公开(公告)号:US20070027081A1

    公开(公告)日:2007-02-01

    申请号:US11385612

    申请日:2006-03-21

    IPC分类号: A61K38/17 A61K38/00

    摘要: The present invention relates to the methods and compositions for the treatment of subjects having compromised bone conditions. Specifically, the invention relates to combinatorial therapeutic strategies including small molecules and peptide mimics of LIM mineralization proteins, particularly LMP-1, to overcome the dose-related translational barriers for BMP-2 therapeutics.

    摘要翻译: 本发明涉及用于治疗受损骨患者的方法和组合物。 具体地,本发明涉及包括LIM矿化蛋白(特别是LMP-1)的小分子和肽模拟物的组合治疗策略,以克服BMP-2治疗剂的剂量相关翻译屏障。

    Methods of expressing LIM mineralization protein in non-osseous cells
    3.
    发明申请
    Methods of expressing LIM mineralization protein in non-osseous cells 有权
    在非骨细胞中表达LIM矿化蛋白的方法

    公开(公告)号:US20100239545A9

    公开(公告)日:2010-09-23

    申请号:US10292951

    申请日:2002-11-13

    摘要: Methods of expressing LIM mineralization protein in non-osseous mammalian cells, such as stem cells or intervertebral disc cells (e.g., cells of the annulus fibrosus, or cells of the nucleus pulposus) are described. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter. Transfection may be accomplished ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid. Expression of the LIM mineralization protein can stimulate proteoglycan and/or collagen production in cells capable of producing proteoglycyan and/or collagen. Methods for treating disc disease associated with trauma or disc degeneration are also described.

    摘要翻译: 描述了在非骨骼哺乳动物细胞中表达LIM矿化蛋白的方法,例如干细胞或椎间盘细胞(例如,纤维环的细胞或髓核的细胞)。 所述方法涉及用分离的核酸转染细胞,所述分离的核酸包含可操作地连接到启动子的编码LIM矿化蛋白的核苷酸序列。 转染可以通过直接注射病毒或裸露DNA或非病毒载体如质粒在体内或体内完成。 LIM矿化蛋白的表达可以刺激能够产生蛋白多糖和/或胶原的细胞中的蛋白聚糖和/或胶原产生。 还描述了与创伤或椎间盘退变相关的椎间盘疾病的治疗方法。

    Methods of inducing or increasing the expression of proteoglycans such as aggrecan in cells
    5.
    发明申请
    Methods of inducing or increasing the expression of proteoglycans such as aggrecan in cells 审中-公开
    在细胞中诱导或增加蛋白聚糖如聚集蛋白聚糖的表达的方法

    公开(公告)号:US20070134218A1

    公开(公告)日:2007-06-14

    申请号:US11602805

    申请日:2006-11-21

    IPC分类号: A61K48/00

    摘要: Methods of inducing the expression of a proteoglycan such as aggrecan in a cell are described. A method is described which includes transfecting a cell with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter. The LIM mineralization protein can be rLMP, hLMP-1, hLMP-1s, or hLMP-3. Transfection maybe accomplished ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid. The method can be used to induce proteoglycan synthesis in osseous cells or to stimulate proteoglycan and/or collagen production in cells capable of producing proteoglycan and/or collagen (e.g., intervertebral disc cells including cells of the nucleus pulposus and annulus fibrosus).

    摘要翻译: 描述了在细胞中诱导蛋白聚糖如聚集蛋白聚糖表达的方法。 描述了一种方法,其包括用分离的核酸转染细胞,所述分离的核酸包含可操作地连接于启动子的编码LIM矿化蛋白的核苷酸序列。 LIM矿化蛋白可以是rLMP,hLMP-1,hLMP-1或hLMP-3。 转染可以通过直接注射病毒或裸DNA或通过非病毒载体如质粒在体内或体内完成。 该方法可用于在骨细胞中诱导蛋白聚糖合成或刺激能够产生蛋白聚糖和/或胶原的细胞(例如包括髓核细胞和纤维环的椎间盘细胞)中的蛋白聚糖和/或胶原产生。

    Methods of inducing or increasing the expression of proteoglycans such as aggrecan in cells
    6.
    发明申请
    Methods of inducing or increasing the expression of proteoglycans such as aggrecan in cells 审中-公开
    在细胞中诱导或增加蛋白聚糖如聚集蛋白聚糖的表达的方法

    公开(公告)号:US20090304649A9

    公开(公告)日:2009-12-10

    申请号:US11602805

    申请日:2006-11-21

    IPC分类号: A61K48/00

    摘要: Methods of inducing the expression of a proteoglycan such as aggrecan in a cell are described. A method is described which includes transfecting a cell with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter. The LIM mineralization protein can be rLMP, hLMP-1, hLMP-1s, or hLMP-3. Transfection maybe accomplished ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid. The method can be used to induce proteoglycan synthesis in osseous cells or to stimulate proteoglycan and/or collagen production in cells capable of producing proteoglycan and/or collagen (e.g., intervertebral disc cells including cells of the nucleus pulposus and annulus fibrosus).

    摘要翻译: 描述了在细胞中诱导蛋白聚糖如聚集蛋白聚糖表达的方法。 描述了一种方法,其包括用分离的核酸转染细胞,所述分离的核酸包含可操作地连接于启动子的编码LIM矿化蛋白的核苷酸序列。 LIM矿化蛋白可以是rLMP,hLMP-1,hLMP-1或hLMP-3。 转染可以通过直接注射病毒或裸DNA或通过非病毒载体如质粒在体内或体内完成。 该方法可用于在骨细胞中诱导蛋白聚糖合成或刺激能够产生蛋白聚糖和/或胶原的细胞(例如包括髓核细胞和纤维环的椎间盘细胞)中的蛋白聚糖和/或胶原产生。

    Compositions comprising biomembrane sealing agent for treatment of pain or inflammation, and methods of use
    7.
    发明申请
    Compositions comprising biomembrane sealing agent for treatment of pain or inflammation, and methods of use 有权
    包含用于治疗疼痛或炎症的生物膜密封剂的组合物和使用方法

    公开(公告)号:US20070258938A1

    公开(公告)日:2007-11-08

    申请号:US11418153

    申请日:2006-05-03

    摘要: The invention provides methods and kits for treatment of pain or inflammation. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, an intra-articular administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.

    摘要翻译: 本发明提供了治疗疼痛或炎症的方法和试剂盒。 在一个实施方案中,试剂盒包括生物膜密封剂,例如PEG,以及生物活性剂,例如镁化合物。 生物膜密封剂和/或生物活性剂,静脉内给药,肌内给药,鞘内给药,皮下给药,硬膜外给药,胃肠外给药,关节内给药,直接施用于或邻近 病理状况及其任何组合。 或者,生物膜密封剂和/或生物活性剂可以从泵或植入物递送。

    Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
    8.
    发明申请
    Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use 有权
    包含用于治疗神经元损伤的生物膜密封剂的组合物和使用方法

    公开(公告)号:US20070259044A1

    公开(公告)日:2007-11-08

    申请号:US11418152

    申请日:2006-05-03

    摘要: The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.

    摘要翻译: 本发明提供用于治疗神经元损伤的组合物,试剂盒和方法。 在一个实施方案中,组合物包含生物膜密封剂,例如PEG,以及生物活性剂,例如镁化合物。 静脉内给药,肌内给药,鞘内给药,皮下给药,硬膜外给药,胃肠外给药,直接施用于病理状况的部位或其附近的生物膜密封剂和/或生物活性剂,以及任何 其组合。 或者,生物膜密封剂和/或生物活性剂可以从泵或植入物递送。

    Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation
    9.
    发明申请
    Isolation of bone marrow fraction rich in connective tissue growth components and the use thereof to promote connective tissue formation 审中-公开
    分离富含结缔组织生长成分的骨髓部分及其促进结缔组织形成的用途

    公开(公告)号:US20050130301A1

    公开(公告)日:2005-06-16

    申请号:US10887275

    申请日:2004-07-08

    摘要: A bone marrow isolate rich in one or more connective tissue growth components, methods of forming the isolate, and methods of promoting connective tissue growth using the isolate are described. A biological sample comprising bone marrow is centrifuged to separate the sample into fractions including a fraction rich in connective tissue growth components. The fraction rich in connective tissue growth components is then isolated from the separated sample. The isolate can be used directly or combined with a carrier and implanted into a patient at a tissue (e.g., bone) defect site. The biological sample can comprise bone marrow and whole blood. The isolate can be modified (e.g., by transfection with a nucleic acid encoding an osteoinductive polypeptide operably linked to a promoter) prior to application to the tissue defect site. The isolate can be made and applied to the tissue defect site in a single procedure (i.e., intraoperatively).

    摘要翻译: 描述了富含一种或多种结缔组织生长组分的骨髓分离物,形成分离物的方法和使用该分离物促进结缔组织生长的方法。 将包含骨髓的生物样品离心以将样品分离成包含富含结缔组织生长成分的馏分。 然后从分离的样品中分离富含结缔组织生长成分的级分。 分离物可以直接使用或与载体组合使用,并在组织(例如骨)缺陷部位植入患者体内。 生物样品可以包括骨髓和全血。 在施用于组织缺损位点之前,可以修饰分离物(例如,通过用编码与促进剂可操作地连接的骨诱导多肽的核酸进行转染)。 分离物可以以单一程序(即在手术中)制成并应用于组织缺损部位。

    Dexamethasone formulations in a biodegradable material
    10.
    发明授权
    Dexamethasone formulations in a biodegradable material 有权
    地塞米松配方可生物降解材料

    公开(公告)号:US08524267B2

    公开(公告)日:2013-09-03

    申请号:US12105864

    申请日:2008-04-18

    IPC分类号: A61F2/00 A61K9/00

    摘要: Effective treatments of acute pain for extended periods of time are provided. Through the administration of an effective amount of dexamethasone at or near a target site, one can relieve pain cause by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.

    摘要翻译: 提供了长期急性疼痛的有效治疗方法。 通过在目标部位或附近施用有效量的地塞米松,可以减轻不同来源的疼痛,包括但不限于椎间盘突出症(即坐骨神经痛),脊椎脱位,狭窄,恶性背痛和关节疼痛 作为手术附带的疼痛。 当在可生物降解的聚合物中提供适当的制剂时,这种缓解可以持续至少二十五天。 在一些实施例中,浮雕可以是至少五十天,至少一百天,至少一百三十五天或至少一百八十天。